MX2023011655A - Inhibidores terapeuticos de la se?alizacion de gdf15. - Google Patents
Inhibidores terapeuticos de la se?alizacion de gdf15.Info
- Publication number
- MX2023011655A MX2023011655A MX2023011655A MX2023011655A MX2023011655A MX 2023011655 A MX2023011655 A MX 2023011655A MX 2023011655 A MX2023011655 A MX 2023011655A MX 2023011655 A MX2023011655 A MX 2023011655A MX 2023011655 A MX2023011655 A MX 2023011655A
- Authority
- MX
- Mexico
- Prior art keywords
- gdf15
- signalling
- gfral
- relates
- therapeutic inhibitors
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Genetics & Genomics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB2104556.2A GB202104556D0 (en) | 2021-03-31 | 2021-03-31 | Therapeutic inhibitors of GDF15 signalling |
| GBGB2107331.7A GB202107331D0 (en) | 2021-05-21 | 2021-05-21 | Therapeutic inhibitors of GDF15 signalling |
| GBGB2108170.8A GB202108170D0 (en) | 2021-06-08 | 2021-06-08 | Theraputic inhibitors of GDF15 Signalling |
| PCT/EP2022/058669 WO2022207846A1 (en) | 2021-03-31 | 2022-03-31 | Therapeutic inhibitors of gdf15 signalling |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023011655A true MX2023011655A (es) | 2023-10-11 |
Family
ID=81580347
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023011655A MX2023011655A (es) | 2021-03-31 | 2022-03-31 | Inhibidores terapeuticos de la se?alizacion de gdf15. |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20240182585A1 (enExample) |
| EP (1) | EP4314071A1 (enExample) |
| JP (1) | JP2024511853A (enExample) |
| KR (1) | KR20230165285A (enExample) |
| AU (1) | AU2022251923A1 (enExample) |
| BR (1) | BR112023020152A2 (enExample) |
| CA (1) | CA3215737A1 (enExample) |
| CO (1) | CO2023013791A2 (enExample) |
| IL (1) | IL307382A (enExample) |
| MX (1) | MX2023011655A (enExample) |
| WO (1) | WO2022207846A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017172260A1 (en) | 2016-03-31 | 2017-10-05 | Ngm Bioparmaceuticals, Inc. | Binding proteins and methods of use thereof |
| IT202300006387A1 (it) * | 2023-03-31 | 2024-10-01 | Univ Degli Studi Roma La Sapienza | Inibitore del recettore gfral per uso nel trattamento della sclerosi laterale amiotrofica |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6121022A (en) | 1995-04-14 | 2000-09-19 | Genentech, Inc. | Altered polypeptides with increased half-life |
| US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
| JP4336498B2 (ja) | 2000-12-12 | 2009-09-30 | メディミューン，エルエルシー | 延長した半減期を有する分子ならびにその組成物および用途 |
| US20050266425A1 (en) | 2003-12-31 | 2005-12-01 | Vaccinex, Inc. | Methods for producing and identifying multispecific antibodies |
| ES2518865T3 (es) | 2004-04-13 | 2014-11-05 | St Vincent's Hospital Sydney Limited | Agente de inhibición de MIC-1 |
| JOP20080381B1 (ar) | 2007-08-23 | 2023-03-28 | Amgen Inc | بروتينات مرتبطة بمولدات مضادات تتفاعل مع بروبروتين كونفيرتاز سيتيليزين ككسين من النوع 9 (pcsk9) |
| CA2783934A1 (en) | 2009-12-11 | 2011-06-16 | Genecode As | Methods of facilitating neural cell survival using gdnf family ligand (gfl) mimetics or ret signaling pathway activators |
| WO2013012648A1 (en) | 2011-07-15 | 2013-01-24 | Emory University | Gdf15 in diagnostic and therapeutic applications |
| CN102321173B (zh) | 2011-08-12 | 2013-04-03 | 中国医学科学院肿瘤研究所 | 人源化巨噬细胞抑制因子1单克隆抗体及其应用 |
| PT2900263T (pt) | 2012-09-26 | 2019-07-29 | Univ Wuerzburg J Maximilians | Anticorpos monoclonais contra o factor de crescimento e diferenciaçao 15 (gdf-15) |
| CA2896076C (en) | 2012-12-21 | 2022-12-06 | Aveo Pharmaceuticals, Inc. | Anti-gdf15 antibodies |
| EP3122775B1 (en) | 2014-03-26 | 2019-11-13 | Julius-Maximilians-Universität Würzburg | Monoclonal antibodies to growth and differentiation factor 15 (gdf-15), and uses thereof for treating cancer cachexia and cancer |
| HUE054670T2 (hu) | 2014-09-25 | 2021-09-28 | Aveo Pharmaceuticals Inc | Módszer cachexia visszafordítására és túlélés megnövelésére egy GDF15 modulátor és egy rákellenes szer adagolásával |
| JP6925326B2 (ja) | 2015-10-02 | 2021-08-25 | ユリウス−マクシミリアン−ウニヴェルシテート・ヴュルツブルク | ヒト成長分化因子１５（ｇｄｆ−１５）の阻害剤及び免疫チェックポイントブロッカーを使用する併用療法 |
| WO2017121865A1 (en) | 2016-01-15 | 2017-07-20 | Novo Nordisk A/S | Mic-1 receptor and uses thereof |
| JP2019510739A (ja) * | 2016-02-29 | 2019-04-18 | イーライ リリー アンド カンパニー | Ｇｆｒａｌ受容体療法 |
| AU2017228489A1 (en) | 2016-03-04 | 2018-09-06 | Ngm Biopharmaceuticals, Inc. | Compositions and methods for modulating body weight |
| WO2017172260A1 (en) | 2016-03-31 | 2017-10-05 | Ngm Bioparmaceuticals, Inc. | Binding proteins and methods of use thereof |
| CN109071647B (zh) | 2016-04-27 | 2022-11-22 | 诺华股份有限公司 | 抗生长分化因子15的抗体及其用途 |
-
2022
- 2022-03-31 EP EP22720935.0A patent/EP4314071A1/en active Pending
- 2022-03-31 IL IL307382A patent/IL307382A/en unknown
- 2022-03-31 CA CA3215737A patent/CA3215737A1/en active Pending
- 2022-03-31 MX MX2023011655A patent/MX2023011655A/es unknown
- 2022-03-31 KR KR1020237037287A patent/KR20230165285A/ko active Pending
- 2022-03-31 WO PCT/EP2022/058669 patent/WO2022207846A1/en not_active Ceased
- 2022-03-31 BR BR112023020152A patent/BR112023020152A2/pt unknown
- 2022-03-31 US US18/284,952 patent/US20240182585A1/en active Pending
- 2022-03-31 JP JP2023560403A patent/JP2024511853A/ja active Pending
- 2022-03-31 AU AU2022251923A patent/AU2022251923A1/en active Pending
-
2023
- 2023-10-19 CO CONC2023/0013791A patent/CO2023013791A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2022207846A1 (en) | 2022-10-06 |
| EP4314071A1 (en) | 2024-02-07 |
| BR112023020152A2 (pt) | 2023-11-14 |
| CO2023013791A2 (es) | 2024-01-25 |
| IL307382A (en) | 2023-11-01 |
| KR20230165285A (ko) | 2023-12-05 |
| JP2024511853A (ja) | 2024-03-15 |
| CA3215737A1 (en) | 2022-10-06 |
| US20240182585A1 (en) | 2024-06-06 |
| AU2022251923A1 (en) | 2023-11-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Shimizu et al. | Indoxyl sulfate upregulates renal expression of MCP-1 via production of ROS and activation of NF-κB, p53, ERK, and JNK in proximal tubular cells | |
| Gäbele et al. | Role of TLR9 in hepatic stellate cells and experimental liver fibrosis | |
| MX2025008493A (es) | Agentes de union a fibroblastos y uso de estos | |
| GEP20125471B (en) | Compositions monovalent for cd40l binding and methods of use | |
| EP4385520A3 (en) | Glycotargeting therapeutics | |
| NZ759601A (en) | Aggrecan binding immunoglobulins | |
| EA201490393A1 (ru) | Соматотропный гормон пролонгированного действия и способы его получения | |
| NO20083793L (no) | Antistoffer mot amyloid-beta peptid | |
| PH12012501549A1 (en) | Cd127 binding proteins | |
| MX2017006639A (es) | Metodos y composiciones para preservar la masa corporal magra y promover la perdida de grasa durante la perdida de peso. | |
| MX2018006477A (es) | Anticuerpos y metodos de uso de estos. | |
| RU2017142932A (ru) | Фармацевтические и пищевые композиции для индуцирования насыщения и продления сытости у нуждающихся в этом субъектов | |
| MX2021015651A (es) | Proteinas de union a la proteina accesoria del receptor de interleucina-1 (il1rap). | |
| MX2025006615A (es) | Metodos para alterar la composicion corporal | |
| CO2023013791A2 (es) | Inhibidores terapéuticos de la señalización de gdf15 | |
| LT4230650T (lt) | Antikūnai, gebantys susirišti su koronaviruso sars-cov-2 spyglio baltymu | |
| IL315020A (en) | Antibodies capable of binding to the spike protein of the SARS-COV-2 coronavirus | |
| EA201691436A1 (ru) | Композиция, включающая окру для применения в уменьшении абсорбции пищевого жира | |
| CO2020004801A2 (es) | Uso de suplementos de aminoácidos para mejorar la síntesis de proteínas musculares | |
| WO2008083169A3 (en) | Compositions and methods for the treatment of immunologic disorders | |
| WO2010034514A3 (de) | Cfhr1 als inhibitor der c5 konvertase zur behandlung von autoimmunerkrankungen | |
| JOP20210111A1 (ar) | نظائر عامل gdf15 وطرق استخدامه في تقليل وزن الجسم و/أو تخفيض امتصاص الطعام | |
| Inubushi et al. | Lactoferrin inhibits infection-related osteoclastogenesis without interrupting compressive force-related osteoclastogenesis | |
| MX2024001644A (es) | Anticuerpos contra el receptor alfa de la interleucina-4 humana. | |
| RU2013147976A (ru) | ИНГИБИТОРЫ Trmp5 ПОДДЕРЖИВАЮТ СНИЖЕНИЕ МАССЫ ТЕЛА БЕЗ УМЕНЬШЕНИЯ ПОТРЕБЛЕНИЯ ПИЩИ |